Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Reference interval and the role of plasma oligomeric beta amyloid in screening of risk groups for cognitive dysfunction at health checkups.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: United States NLM ID: 8801384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2825 (Electronic) Linking ISSN: 08878013 NLM ISO Abbreviation: J Clin Lab Anal Subsets: MEDLINE
    • Publication Information:
      Publication: Hoboken, N.J. : Wiley
      Original Publication: New York : Alan R. Liss, Inc., c1987-
    • Subject Terms:
      Amyloid beta-Peptides/*blood ; Amyloid beta-Peptides/*chemistry ; Biomarkers/*blood ; Cognitive Dysfunction/*diagnosis; Aged ; Aged, 80 and over ; Cognitive Dysfunction/blood ; Cognitive Dysfunction/epidemiology ; Female ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Prospective Studies ; Reference Values ; Republic of Korea/epidemiology ; Risk Factors
    • Abstract:
      Background: Alzheimer's disease (AD) has a prolonged preclinical stage characterized by cognitive dysfunction. Simple, reliable, and noninvasive biomarkers reflecting the pathogenesis of AD are needed for screening cognitive dysfunction in primary health care. The aims of this study were to determine (1) the potential utility of the Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) value in cognitive assessments and (2) the reference interval (RI) of plasma MDS-OAβ values in the general population.
      Methods: This prospective study consecutively recruited 1,594 participants who underwent health checkups including cognitive function examination at 16 health-promotion centers in Korea between December 2020 and January 2021. The inBlood TM OAβ test (PeopleBio, Gyeonggi-do, Republic of Korea) was utilized to quantify MDS-OAβ values in plasma. The reference subjects were obtained among those with normal general cognition on cognitive screening tools. RIs were established according to the CLSI C28-A3 guidelines.
      Results: The median MDS-OAβ value was higher in subjects with Korean Dementia Screening Questionnaire-Cognition (KDSQ-C) scores ≥8 than in those with KDSQ-C scores of 6-7 (P = 0.013). The median MDS-OAβ value was higher in subjects with Mini-Mental State Examination for Dementia Screening (MMSE-DS) scores of 21-26 than in those with MMSE-DS scores ≥27 (P = 0.011). The RI (one-side upper 95th percentile) of the MDS-OAβ value was 0.80 ng/mL (95% confidence interval = 0.78-0.82) in those aged ≥50 years.
      Conclusions: The plasma MDS-OAβ value reflects cognitive function as assessed using the KDSQ-C and MMSE-DS. RIs obtained from a large and cognitively healthy community-based sample are presented.
      (© The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.)
    • References:
      Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):4012-7. (PMID: 19228947)
      Neurology. 2015 Sep 8;85(10):898-904. (PMID: 26109713)
      Psychiatry Investig. 2018 Apr;15(4):384-389. (PMID: 29475235)
      Nat Neurosci. 2012 Sep;15(9):1227-35. (PMID: 22820466)
      J Korean Med Sci. 2014 Jul;29(7):903-12. (PMID: 25045221)
      Lancet Neurol. 2013 Feb;12(2):207-16. (PMID: 23332364)
      Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12. (PMID: 17245412)
      Diagnostics (Basel). 2020 Apr 20;10(4):. (PMID: 32326061)
      J Korean Med Sci. 2019 Apr 15;34(14):e111. (PMID: 30977313)
      N Engl J Med. 2012 Aug 30;367(9):795-804. (PMID: 22784036)
      Curr Alzheimer Res. 2014 May;11(4):325-31. (PMID: 24635842)
      J Clin Lab Anal. 2021 Sep;35(9):e23933. (PMID: 34342379)
      J Alzheimers Dis. 2010;21(2):627-39. (PMID: 20555138)
      Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
      J Gerontol A Biol Sci Med Sci. 2014 Aug;69(8):996-1003. (PMID: 24170673)
      Geriatr Gerontol Int. 2016 Feb;16(2):252-8. (PMID: 25655174)
      Front Neurosci. 2016 Jan 29;10:8. (PMID: 26858588)
      Alzheimers Res Ther. 2019 Oct 25;11(1):89. (PMID: 31651358)
      Int J Nanomedicine. 2018 Feb 08;13:843-856. (PMID: 29467574)
      Alzheimers Res Ther. 2017 Dec 15;9(1):98. (PMID: 29246249)
      J Alzheimers Dis. 2020;75(2):493-499. (PMID: 32310175)
      J Alzheimers Dis. 2018;64(s1):S567-S610. (PMID: 29843241)
      Dement Neurocogn Disord. 2018 Jun;17(2):41-49. (PMID: 30906391)
      Lancet Neurol. 2010 Apr;9(4):363-72. (PMID: 20189881)
      Alzheimers Res Ther. 2017 Oct 17;9(1):86. (PMID: 29041968)
    • Contributed Indexing:
      Keywords: Alzheimer's disease; cognitive assessment; multimer detection system; oligomeric amyloid-β; reference interval
    • Accession Number:
      0 (Amyloid beta-Peptides)
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20210803 Date Completed: 20220117 Latest Revision: 20220117
    • Publication Date:
      20250114
    • Accession Number:
      PMC8418474
    • Accession Number:
      10.1002/jcla.23933
    • Accession Number:
      34342379